MELA Sciences Inc  

(Public, NASDAQ:MELA)   Watch this stock  
Find more results for MELA
1.18
-0.01 (-0.83%)
Real-time:   3:06PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.17 - 1.20
52 week 1.03 - 4.05
Open 1.19
Vol / Avg. 31,033.00/65,457.00
Mkt cap 11.87M
P/E     -
Div/yield     -
EPS -3.63
Shares 9.89M
Beta 0.28
Inst. own 14%
Nov 10, 2015
Q3 2015 MELA Sciences Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 30, 2015
MELA Sciences Inc Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
Aug 13, 2015
Q2 2015 MELA Sciences Inc Earnings Call - Webcast
Aug 13, 2015
Q2 2015 MELA Sciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -1284.29% -1545.90%
Operating margin -1473.81% -2190.38%
EBITD margin - -1620.98%
Return on average assets -89.12% -82.71%
Return on average equity -180.92% -155.87%
Employees 32 -
CDP Score - -

Address

100 Lakeside Dr Ste 100
HORSHAM, PA 19044-2352
United States - Map
+1-215-6193200 (Phone)
+1-914-5913785 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

MELA Sciences, Inc. is a medical device company focused on the commercialization of its product, MelaFind. The Company is engaged in the further design and development of MelaFind and its technology. MelaFind is a non-invasive, point-of-care (in the doctor's office) instrument to aid in the detection of melanoma. MelaFind, features a hand-held component that emits light of multiple wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing classification algorithms, trained on the Company's database of melanomas and benign lesions, to provide information to assist in the management of the patient's disease, including information useful in the decision whether to biopsy the lesion.

Officers and directors

Jeffrey F. O'Donnell Sr. Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Michael R. Stewart President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Robert W. Cook Principal Financial Officer, Treasurer, Secretary
Age: 59
Bio & Compensation  - Reuters
David K. Stone Director
Age: 58
Bio & Compensation  - Reuters
Kathryn B. Swintek Director
Age: 62
Bio & Compensation  - Reuters
LuAnn Via Director
Age: 61
Bio & Compensation  - Reuters
Samuel E. Navarro Independent Director
Age: 59
Bio & Compensation  - Reuters